<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6843">
    <dcterms:title><![CDATA[<strong>Intranasal delivery of Quillaja brasiliensis saponin-based nanoadjuvants improve humoral immune response of influenza vaccine in aged mice</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[QUILLAJA BRASILIENSIS]]></dcterms:subject>
    <dcterms:subject><![CDATA[VACUNAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOTECNOLOGIA]]></dcterms:subject>
    <dcterms:subject><![CDATA[NANOPARTICULAS]]></dcterms:subject>
    <dcterms:subject><![CDATA[MATRICES ISCOM]]></dcterms:subject>
    <dcterms:subject><![CDATA[VIRUS]]></dcterms:subject>
    <dcterms:subject><![CDATA[INFLUENZA]]></dcterms:subject>
    <dcterms:subject><![CDATA[VIA INTRANASAL]]></dcterms:subject>
    <dcterms:subject><![CDATA[RATONES ENVEJECIDOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2024]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Increasing the effectiveness of vaccines against respiratory viruses is particularly relevant for the elderly, since they are prone to develop serious infections due to comorbidities and the senescence of the immune system. The addition of saponin-based adjuvants is an interesting strategy to increase the effectiveness of vaccines. We have previously shown that ISCOM matrices from Q. brasiliensis (IMXQB) are a safe and potent adjuvant. In this study, we evaluated the use of IMXQB as an adjuvant for the seasonal trivalent influenza vaccine (TIV) in an aged mice model. Herein, we show that subcutaneous injection of the adjuvanted vaccine promoted higher titers of IgM, IgG (and isotypes), and serum hemagglutination inhibition titers (HAI). Notably, aged mice immunized by intranasal route also produced higher IgG (and isotypes) and IgA titers up to 120 days after priming, as well as demonstrating an improvement in the HAI antibodies against the TIV. Further, experimental infected aged mice treated once with sera from adult na&iuml;ve mice previously immunized with TIV-IMXQB subcutaneously successfully controlled the infection. Overall, TIV-IMXQB improved the immunogenicity compared to TIV by enhancing systemic and mucosal immunity in old mice conferring a faster recovery after the H1N1pdm09-like virus challenge. Thus, IMXQB nanoparticles may be a promising platform for next-generation viral vaccines.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Silveira, Fernando</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Garc&iacute;a, Florencia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Garc&iacute;a, Gabriel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Chabalgoity, Jos&eacute; A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rossi, Silvina</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Baz, Mariana</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">Vaccines, v. 12, n&ordm; 8, 2024. -- e902</span>]]></dcterms:source>
    <dcterms:publisher><![CDATA[MDPI]]></dcterms:publisher>
    <dcterms:date><![CDATA[2024]]></dcterms:date>
    <dcterms:rights><![CDATA[<div class="element-text">
<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
</div>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[18 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">10.3390/vaccines12080902</span>]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
